Heptares Therapeutics Ltd acquires G7 Therapeutics AG

On December 14, 2016, Heptares Therapeutics Ltd, the wholly-owned subsidiary of Sosei Group Corporation based in Hertfordshire (UK), successfully completed the acquisition of all shares in G7 Therapeutics AG for a total purchase price of CHF 12 million.

G7 Therapeutics AG is a Swiss-based privately held drug discovery and development company with a focus on GPCR-targeted structure-based drug design and development. Lenz & Staehelin advised the sellers and G7 Therapeutics AG in this transaction.

The team was led by partner Beat Kühni (Corporate and M&A) and included Dominik Kaczmarczyk, Andreas Hinsen, Elia Schunck and Marc Zimmermann (all Corporate and M&A) as well as counsels Lara Dorigo (Intellectual Property) and Franziska Stadtherr-Glättli (Tax).